RecruitingEarly Phase 1NCT06959979

Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

Studying Medulloblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Intervention
CDK4/6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib)(drug)
Enrollment
60 target
Eligibility
0-18 years · All sexes
Timeline
2024 – 2026

Study locations (1)

Collaborators

University of Rome Tor Vergata · Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello · Università degli Studi di Enna Kore

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06959979 on ClinicalTrials.gov

Other trials for Medulloblastoma

Additional recruiting or active studies for the same condition.

See all trials for Medulloblastoma →

← Back to all trials